my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
Nobilon International BV, part of Organon, was founded in 2003. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines.
Nobilon draws on expertise from its related businesses Organon, Intervet and Diosynth.
Organon is a leading international player in several key areas of human pharmaceuticals, in particular prescription medicines.
Intervet is one of the world’s largest animal healthcare companies, supplying customers with animal healthcare products, including vaccines and pharmaceuticals.
Diosynth plays a prominent global role in the production of complex active (bio)pharmaceutical ingredients.
Through the establishment of Nobilon International, it is aimed to harvest some of the synergies that exist between these businesses and to diversify further into biotechnology. Organon has valuable knowledge in drug development in the field of immunology and biotechnology of human therapeutics. Diosynth will contribute through its experience in process development and production of recombinant proteins, synthetic peptides and monoclonal antibodies. Intervet, with a leadership position in animal vaccines, will bring its research know-how and technological expertise in vaccines to the venture.
Nobilon intends to become a fully integrated biotechnology company encompassing research, development, registration, production and commercialization of selected vaccines.
Industrial Sectors
Watchlist
This is where you can add this company to your personal favourites
Nobilon advances intranasal seasonal influenza vaccine into proof of concept study
Nobilon, the human vaccine business unit of Schering-Plough Corporation, announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use. “We are encouraged by the continuation of the clini ... more
Nobilon advances first vaccine into human trials
Nobilon, the human vaccine business unit of Schering-Plough Corporation, announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal ... more
European expert consortium combines forces to develop a novel pandemic influenza vaccine
A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund t ... more
Nobilon International BV, part of Organon, was founded in 2003. It has production and R&D facilities in Boxmeer and Oss, the Netherlands. The biotechnology company is dedicated to develop, produce and market human vaccines. Nobilon draws on expertise from its related businesses Organon, In ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
